Clinical Trials

  • Clinical Trials
  • Preview of Mirogabalin Human Abuse Potential Case Study
    Download a copy of this HAP case study.

    In June 2024, the U.S. Food and Drug Administration (FDA) published a draft guidance to ensure greater diversity in clinical trials, which is expected to become a final guidance by June 2025.

    There’s a lot of life science content out there, which is why we’ve curated a selection of our expert insights, tips, case studies, and scientific and regulatory information for your convenience. Catch up on what you might have missed below!

    Development of the Subject-Rated Comprehensive Drug Withdrawal Scale (CDWS) to Evaluate the Physical Dependence Potential of Investigational Drugs

    Pragmatic Considerations for the Application of Physical Withdrawal Assessments in Patient Studies

    The Challenges With Outsourcing Drug Development

    In a Biopharma Dive survey, 45% of the over 143 biopharmaceutical executives surveyed cited the inability to adhere to tight deadlines as a common challenge in preclinical and Phase I clinical development.

    Early-phase drug development is an ever-changing landscape, as emerging science leads to new promising areas of research for the treatment of human health issues. In this blog article, we review some of these areas of investigation where Altasciences has robust expertise and solution offerings.

     

    Altasciences is leading the conversation on change in the drug development industry as part of a new documentary series for the 2024 Global Health Summit, hosted alongside the WHO’s 77th World Health Assembly in Geneva in May. The mini documentary explores transformation in the slow-to-change drug development industry.

    First-in-Human Solution for Small and Large Molecules

    GETTING TO THE HEART OF SCIENCE WITH MARTA RODRIGUEZ

    Marta Rodriguez, Director of Clinical Operations at Altasciences
    Marta Rodriguez, Altasciences

    At the heart of science are stories—stories of expe

    Subscribe to Clinical Trials